Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer


OKUTURLAR Y., Gunaldi M., Kocoglu H., Hursitoglu M., GEDİKBAŞI A., Acarer D., ...More

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.14, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14
  • Publication Date: 2018
  • Doi Number: 10.4103/0973-1482.235355
  • Journal Name: JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: Arylesterase, breast cancer, cancer risk, cut-off value, neoadjuvant, paraoxonase, screening, BODY-MASS INDEX, COLORECTAL-CANCER, OXIDATIVE STRESS, CARCINOGENESIS, INFLAMMATION, POLYMORPHISM, RADICALS, PON1, RISK
  • Istanbul University Affiliated: Yes

Abstract

Aim: The aims of this study are to evaluate the serum levels of paraoxonase (PON) and arylesterase (ARE) in breast cancer (BC) patients; to determine their relationship with chemotherapy requirements in BC; and to find a cut-off value to assess subjects with a higher risk of BC.